| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project
|
McHugh, Gillian S
|
|
2010
|
7 |
1 |
p. 44-57
|
article
|
| 2 |
Biobanking, consent, and commercialization in international genetics research: the Type 1 Diabetes Genetics Consortium
|
Hall, Mark A
|
|
2010
|
7 |
1 |
p. S33-S45
|
article
|
| 3 |
Collection and processing of whole blood for transformation of peripheral blood mononuclear cells and extraction of DNA: the Type 1 Diabetes Genetics Consortium
|
Rosinger, Silke
|
|
2010
|
7 |
1 |
p. S65-S74
|
article
|
| 4 |
Designing and implementing sample and data collection for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC)
|
Hilner, Joan E
|
|
2010
|
7 |
1 |
p. S5-S32
|
article
|
| 5 |
Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials
|
Doria-Rose, V Paul
|
|
2010
|
7 |
1 |
p. 69-77
|
article
|
| 6 |
Failsafe automation of Phase II clinical trial interim monitoring for stopping rules
|
Day, Roger S
|
|
2010
|
7 |
1 |
p. 78-84
|
article
|
| 7 |
HLA genotyping in the international Type 1 Diabetes Genetics Consortium
|
Mychaleckyj, Josyf C
|
|
2010
|
7 |
1 |
p. S75-S87
|
article
|
| 8 |
Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial
|
Cook, Elise D
|
|
2010
|
7 |
1 |
p. 90-99
|
article
|
| 9 |
Interpreting sexually transmissible infection prevention trials by adjusting for the magnitude of exposure
|
Wilson, David P
|
|
2010
|
7 |
1 |
p. 36-43
|
article
|
| 10 |
Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories
|
Bingley, Polly J
|
|
2010
|
7 |
1 |
p. S56-S64
|
article
|
| 11 |
Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field
|
Wittkop, Linda
|
|
2010
|
7 |
1 |
p. 19-35
|
article
|
| 12 |
2009 Peer Reviewers
|
|
|
2010
|
7 |
1 |
p. 100-101
|
article
|
| 13 |
Principles for defining adverse events in behavioral intervention research: lessons from a family-focused adolescent drug abuse trial
|
Horigian, Viviana E
|
|
2010
|
7 |
1 |
p. 58-68
|
article
|
| 14 |
Quality control of phenotypic forms data in the Type 1 Diabetes Genetics Consortium
|
Perdue, Letitia H
|
|
2010
|
7 |
1 |
p. S46-S55
|
article
|
| 15 |
Summarizing historical information on controls in clinical trials
|
Neuenschwander, Beat
|
|
2010
|
7 |
1 |
p. 5-18
|
article
|
| 16 |
Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study
|
Hsu, Vivien M
|
|
2010
|
7 |
1 |
p. 85-89
|
article
|
Journal description